Your Anti-Inflammatory Protocol Isn't Working. Your Genes May Be Why.

TNF-alpha is one of your immune system’s most potent inflammatory messengers. When an infection or injury occurs, TNF-alpha signals your immune cells to mobilize, increase vascular permeability, and trigger inflammation. It’s a critical part of your defense system. In the short term, this response saves your life.

The TNF -308G>A variant, carried by approximately 30% of people with European ancestry, increases TNF-alpha production significantly. People with the A allele produce more TNF-alpha at baseline and in response to immune challenges. This means your inflammatory response is naturally turned up to a higher setting than most people’s.

You notice this as persistent low-grade inflammation: your skin flares more easily, joint inflammation takes longer to resolve, viral infections trigger worse inflammation than they do for others, and general inflammatory markers stay elevated even during non-stressful periods.

IL-6 is an interleukin that amplifies inflammatory signaling. When TNF-alpha or IL-1B initiate an inflammatory cascade, IL-6 amplifies and sustains it. It also drives neuroinflammation, affecting mood and cognition. Normally, IL-6 production is tightly regulated so inflammation resolves once the threat passes.

The IL6 -174G>C variant is carried by roughly 40% of the population, with C allele carriers producing more IL-6. People with the C allele experience amplified and prolonged inflammatory responses; their immune system doesn’t downregulate inflammation as efficiently. A normal inflammation that should resolve in days lingers for weeks.

You experience this as slow inflammatory recovery, disproportionate reactions to minor stressors, joint inflammation that won’t resolve, brain fog during inflammatory episodes, and mood changes that correlate with inflammatory markers.

SOD2 is the only antioxidant enzyme that works inside your mitochondria, where energy is produced and reactive oxygen species (free radicals) are naturally generated. When ROS accumulate unchecked, they damage mitochondrial DNA, proteins, and lipids. This triggers inflammatory signaling as a danger signal. SOD2 keeps ROS under control, preventing this inflammatory cascade.

The SOD2 Val16Ala variant, present in approximately 40% of people homozygous for the variant allele, reduces SOD2 enzyme efficiency. People with this variant accumulate oxidative stress inside their mitochondria, which continuously triggers inflammatory gene expression. You’re literally burning yourself from the inside.

You notice this as unexplained fatigue alongside inflammation, exercise-induced flares (because exertion generates ROS), inflammation that worsens with stress (stress increases ROS production), and a tendency toward chronic conditions that correlate with oxidative damage.

MTHFR converts dietary folate into methylfolate, the form your cells use to run methylation reactions. Methylation controls hundreds of cellular processes, including immune regulation and inflammation control. When methylation is impaired, your cells can’t properly regulate inflammatory gene expression. Inflammation becomes harder to turn off.

The MTHFR C677T variant, carried by roughly 35-40% of the population, reduces enzyme activity by 40-70%. People with this variant cannot convert dietary folate efficiently, leaving them functionally depleted in the active form their immune system needs to suppress inflammation. You’re eating enough folate, but your cells aren’t accessing it.

You experience this as inflammation that doesn’t respond to diet alone, fatigue that worsens with B vitamin deficiency, mood changes tied to inflammatory episodes, and a tendency toward elevated homocysteine (which itself drives inflammation).

GSTM1 is a detoxification enzyme that binds to harmful compounds (pesticides, pollutants, oxidized lipids) and neutralizes them. Without GSTM1, these compounds accumulate in your tissues and trigger chemical-driven immune activation. Your immune system perceives them as threats and mounts inflammatory responses. Toxin exposure becomes an inflammatory stimulus.

Approximately 50% of the population carries the GSTM1 null genotype, a complete gene deletion. People with this deletion lose GSTM1 entirely and cannot effectively detoxify a major class of environmental chemicals. Chemical and pesticide exposure triggers disproportionate inflammation in you compared to people with active GSTM1.

You notice this as flares triggered by specific exposures: pesticide residue on non-organic produce, air pollution, cleaning products, certain personal care items, or mold exposure. Your inflammation responds to exposure avoidance in ways it doesn’t respond to dietary interventions.

CRP is an acute-phase protein produced by your liver in response to inflammation. It’s one of the primary markers doctors measure to assess inflammation. CRP itself also amplifies inflammation by triggering complement activation and increasing vascular permeability. Normally, CRP rises during inflammation, then falls once the trigger resolves.

The CRP +1444C>T variant, present in approximately 30% of the population, increases CRP expression. People with the T allele have higher baseline CRP levels and react more intensely to inflammatory triggers, producing larger CRP increases. Your inflammatory baseline is set higher than average.

You experience this as chronically elevated inflammatory markers even during periods when you don’t feel acutely inflamed, disproportionate inflammatory responses to mild triggers, and slow resolution of inflammation after infections or injuries.